S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
LON:OXB

Oxford Biomedica (OXB) Share Price, News & Analysis

GBX 202.50
-7.00 (-3.34%)
(As of 04/12/2024 ET)
Today's Range
198
209.67
50-Day Range
167.20
215
52-Week Range
164.29
474.50
Volume
194,395 shs
Average Volume
228,489 shs
Market Capitalization
£202.42 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 498.75

Oxford Biomedica MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
146.3% Upside
GBX 498.75 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

OXB stock logo

About Oxford Biomedica Stock (LON:OXB)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Stock Price History

OXB Stock News Headlines

These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Oxford Biomedica completes acquisition of ABL Europe
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Oxford Biomedica Posts FY Loss
CGT CDMO Market Share and Forecast till 2030
See More Headlines
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 498.75
High Stock Price Target
GBX 1,010
Low Stock Price Target
GBX 180
Potential Upside/Downside
+146.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
£-61,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£119.02 million
Cash Flow
GBX 67.35 per share
Book Value
GBX 178 per share

Miscellaneous

Free Float
N/A
Market Cap
£202.42 million
Optionable
Not Optionable
Beta
1.00
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Stuart Paynter (Age 52)
    CFO & Director
    Comp: $832k
  • Dr. Frank Mathias (Age 62)
    CEO & Director
  • Mr. Thierry Cournez
    COO & Site Head of UK Operations
  • Dr. James Miskin Ph.D.
    Chief Quality & Technical Officer
  • Mr. Matthew Treagus
    Chief Information Officer & Chief of Staff
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter (Age 51)
    General Counsel & Company Secretary
  • Ms. Lisa James
    Chief People Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Innovation Officer
  • Ms. Kati Hudson
    Head of Intellectual Property and Contracts

OXB Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings
or view top-rated stocks.

What is Oxford Biomedica's stock price target for 2024?

4 equities research analysts have issued 1 year price targets for Oxford Biomedica's stock. Their OXB share price targets range from GBX 180 to GBX 1,010. On average, they predict the company's share price to reach GBX 498.75 in the next twelve months. This suggests a possible upside of 146.3% from the stock's current price.
View analysts price targets for OXB
or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2024?

Oxford Biomedica's stock was trading at GBX 220 at the start of the year. Since then, OXB shares have decreased by 8.0% and is now trading at GBX 202.50.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OXB) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners